Cardioversion in the RE-LY Trial
Links shared publicly online about this topic.
- 135total visits
Cardioversion in the RE-LY Trial
View full resource at physiciansweekly.com
Tags: Hospital, Anti-Clotting Medication, Anticoagulant, Coumadin, Physician, Hospitals, News, Medical
Most Recently Shared on July 19, 2011 at 12:38 pm By:
Dabigatran appears to avoid some of the drawbacks associated with warfarin in the setting of cardioversion: http://bit.ly/q5L3A4
Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial
annals.org — “Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial” View full resource at annals.org
Most Recently Shared on November 21, 2011 at 4:04 pm By:
Annals of Int Med Medical Journal
Risks for Stroke Bleeding & Death in Patients w/ AFib Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score http://t.co/uTCXgRfq
ESC | Congresses | ESC Congress 2011 | ECOST: Safety of implantable cardioverter defibrillator follow-up using remote monitoring: a randomized controlled trial
escardio.org — “Congress report, ESC congress 2011,Hot Line II - Frontiers in interventional and device treatments,Cardioversion / defibrillation” View full resource at escardio.org
Most Recently Shared on August 29, 2011 at 10:50 am By:
European Cardiology Cardiology and Medical Society
ECOST hot line report http://ow.ly/6ffRN #escparis2011
Dabigatran etexilate superior to warfarin for stroke prevention in AF patients
news-medical.net — “New data from two RE-LY trial sub-group analyses show that dabigatran etexilate provides consistent benefits in stroke in atrial fibrillation (AF) compared to well-controlled warfarin, irrespective of whether patients use antiplatelet or other concomitant therapies, such as the anti-arrhythmics amiodarone or verapamil.” View full resource at news-medical.net
Most Recently Shared on August 29, 2011 at 10:37 am By:
Dabigatran etexilate superior to warfarin for stroke prevention in AF patients: New data from two RE-LY trial su... http://t.co/rheVcnc
ESC | Congresses | ESC Congress 2011 | RE-LY: Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY®) trial
escardio.org — “Congress report, ESC congress 2011,Clinical Trial Update I - Drug treatment,Atrial fibrillation (AF)” View full resource at escardio.org
Most Recently Shared on August 28, 2011 at 3:25 pm By:
Michael Katz Internist, Physician, and Doctor
Superiority of 150 mg dose of dabigatran disappears when clopidogrel added. http://ow.ly/6eQtU #escparis2011
Is RE-LY trial (dabi vs warfarin) applicable? http://bit.ly/oObnNR RT @eomastro: @stopafib Studies comparing dabigatran & acenocoumarol?
stopafib.org — “Is RE-LY trial (dabi vs warfarin) applicable? http://bit.ly/oObnNR RT @eomastro: @stopafib Studies comparing dabigatran & acenocoumarol?” View full resource at stopafib.org
Most Recently Shared on August 5, 2011 at 1:50 pm By:
Is RE-LY trial (dabi vs warfarin) applicable? http://bit.ly/oObnNR RT @eomastro: @stopafib Studies comparing dabigatran & acenocoumarol?
theheart.org: trusted cardiology news and opinions
theheart.org — “The latest developments in cardiology and cardiovascular research, including heartwire news and commentary by some of the world's top cardiologists. Sign up for free.” View full resource at theheart.org
Most Recently Shared on July 14, 2011 at 4:37 pm By:
Time to revisit dabigatran dose in the US?: Researchers say new bleeding-risk data from the RE-LY trial suggest ... http://bit.ly/ouIekN
ESC | Congresses | ESC Congress 2011 | Scientific Programme | Types of sessions and special features | Hot Lines, Clinical Trial Updates, Clinical Registry Highlights
escardio.org — “ESC | Congresses | ESC Congress 2011 | Scientific Programme | Types of sessions and special features | Hot Lines, Clinical Trial Updates, Clinical Registry Highlights” View full resource at escardio.org
Most Recently Shared on June 29, 2011 at 2:46 pm By:
We'll publish a full list @ theheart.org, but in the meantime find them here http://t.co/Bk6frYN by searching "Hot Line" under session type.
theheart.org: trusted cardiology news and opinions
theheart.org — “The latest developments in cardiology and cardiovascular research, including heartwire news and commentary by some of the world's top cardiologists. Sign up for free.” View full resource at theheart.org
Most Recently Shared on May 31, 2011 at 7:43 pm By:
Time to revisit dabigatran dose in the US?: Researchers say new bleeding-risk data from the RE-LY trial suggest ... http://bit.ly/mT53uZ
New Subanalyses of the RE-LY Trial Showed Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scores and Types of Non-Valvular Atrial Fibrillation - Health News - redOrbit
redorbit.com — “RIDGEFIELD, Conn., April 4, 2011 /PRNewswire/ -- Two new retrospective subanalyses of the RE-LY(R) trial, involving Pradaxa(R) (dabigatran etexilate mesylate) capsules, suggested that the reduction in stroke risk achieved with PRADAXA 150mg over warfarin (1) occurred irrespective of CHA2DS2-VASc risk score (2) and the type of non-valvular atrial fibrillation (NVAF) (permanent, persistent and paroxysmal)(3).” View full resource at redorbit.com
Most Recently Shared on April 4, 2011 at 5:52 pm By:
New Subanalyses of the RE-LY Trial Showed Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scor... http://bit.ly/dH9RNZ
Dabigatran Etexilate vs. Warfarin in Different Types of Atrial Fibrillation - MPR
empr.com — “A subgroup analysis from the RE-LY trial has demonstrated that in patients with atrial fibrillation (AF), twice-daily dabigatran etexilate has better efficacy and lower rates of major bleeding when compared with warfarin, as reported at ACC.11, the American College of Cardiology--™s 60th Annual Scientific Session.” View full resource at empr.com
Most Recently Shared on April 4, 2011 at 3:51 pm By:
MPR News: Dabigatran Etexilate vs. Warfarin in Different Types of Atrial Fibrillation: A subgroup analysis from ... http://bit.ly/f00SCu
theheart.org: trusted cardiology news and opinions
theheart.org — “The latest developments in cardiology and cardiovascular research, including heartwire news and commentary by some of the world's top cardiologists. Sign up for free.” View full resource at theheart.org
Most Recently Shared on January 9, 2011 at 11:24 am By:
RE-LY: Stroke risk at AF cardioversion similar on dabigatran or warfarin: The newly available oral anticoagulant... http://bit.ly/fWEGtI
theheart.org: trusted cardiology news and opinions
theheart.org — “The latest developments in cardiology and cardiovascular research, including heartwire news and commentary by some of the world's top cardiologists. Sign up for free.” View full resource at theheart.org
Most Recently Shared on January 7, 2011 at 9:40 pm By:
RE-LY: Stroke risk at AF cardioversion similar on dabigatran or warfarin: The newly available oral anticoagulant... http://bit.ly/feoVgx
New Sub-Analysis Of RE-LY Trial Examines Pradaxa In Patients With Atrial Fibrillation Undergoing Cardioversion
medicalnewstoday.com — “Results of a post-hoc analysis of the RE-LY® trial among patients with non-valvular atrial fibrillation (NVAF) undergoing cardioversion, a treatment to convert an abnormal heartbeat back to no” View full resource at medicalnewstoday.com
Most Recently Shared on January 6, 2011 at 4:56 pm By:
MNT Cardiovascular Health News
New Sub-Analysis Of RE-LY Trial Examines Pradaxa In Patients With Atrial Fibrillation Undergoing Cardioversion http://mnt.to/3PHb
New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion - Drugs.com MedNews
drugs.com — “Data from largest cardioversion analysis to date show low frequency of stroke and major bleeding with Pradaxa Results of a post-hoc analysis of the RE-LY trial” View full resource at drugs.com
Most Recently Shared on January 5, 2011 at 3:16 pm By:
Drugs and Devices OW OW Health
New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardiover... http://bit.ly/eT8aVr #drug
Advertisement
